PRQRNasdaqPharmaceutical PreparationsFiscal year ends December 31
ProQR Therapeutics N.V.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 12, 2026
$1.31+0.00 (0.00%)
Close on Oct 19, 2026
Ownership
Who owns ProQR Therapeutics's shares
Held by institutions
–
Shares held, 13F filers
Institutional holders
–
Net institutional buying
–
Insider trades, 12 months
5 buys · 0 sales
Net bought $1.34M
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Adage Capital Management, L.P. | 9,602,280 | 9.30% | 13G (passive) | Dec 31, 2024 |
| Aberdeen Group plc | 8,932,507 | 6.33% | 13G (passive) | Jun 30, 2026 |
| Phillip Gross | 8,102,098 | 7.70% | 13G (passive) amendment | Mar 31, 2025 |
| Robert Atchinson | 6,601,938 | 6.27% | 13G (passive) amendment | Jun 30, 2025 |
| Patrick Johan Hendrik Krol | 5,528,862 | 5.20% | 13G (passive) amendment | Jul 15, 2026 |
| ELI LILLY & Co | 21,995,880 | 15.60% | 13G (passive) amendment | Jun 26, 2026 |
| Van Herk Investments THI B.V. | 15,384,250 | 14.60% | 13D (active) amendment | Jun 2, 2026 |
| Adrianus van Herk | 15,384,250 | 10.90% | 13D (active) amendment | Jun 26, 2026 |
| Onroerend Goed Beheer- en Beleggingsmaatschappij A. van Herk B.V. | 15,384,250 | 10.90% | 13D (active) amendment | Jul 27, 2026 |
| Stichting Administratiekantoor Penulata | 15,384,250 | 14.60% | 13D (active) amendment | Feb 5, 2026 |
| A. van Herk Holding B.V. | 14,329,690 | 13.60% | 13D (active) amendment | Sep 29, 2025 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Boer Daniel Anton de | Chief Executive Officer, Director | 500,000 | 0.47% | Aug 3, 2026 |
| Gerardus Johannes Platenburg | Chief Scientific Officer, Director | 824,388 | 0.78% | Mar 18, 2026 |
| Dennis Hom | Chief Financial Officer | – | – | Mar 18, 2026 |
| Bart Filius | Director | 300,000 | 0.28% | Jul 21, 2026 |
| Gylvin Lykke Hinsch | Director | – | – | Jun 30, 2026 |
| Alison Frances Lawton | Director | – | – | Mar 18, 2026 |
| Martin Alexander Maier | Director | – | – | Mar 18, 2026 |
| Theresa Heggie | Director | 43,623 | 0.04% | Mar 18, 2026 |
| Domenico Valerio | Director | 725,692 | 0.69% | Mar 18, 2026 |
| Begona Carreno-Gomez | Director | – | – | Mar 18, 2026 |
| James Samuel Shannon | Director | 61,538 | 0.06% | Mar 18, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Boer Daniel Anton de Chief Executive Officer, Director | Jul 31, 2026 | Buy | +200,000 | $1.77 | $354.00K | 500,000 |
| Bart Filius Director | Jul 17, 2026 | Buy | +150,000 | $1.72 | $258.00K | 300,000 |
| Boer Daniel Anton de Chief Executive Officer, Director | Jul 9, 2026 | Buy | +150,000 | $1.74 | $261.00K | 300,000 |
| Boer Daniel Anton de Chief Executive Officer, Director | Jul 7, 2026 | Buy | +150,000 | $1.59 | $238.50K | 150,000 |
| Bart Filius Director | Jun 26, 2026 | Buy | +150,000 | $1.54 | $231.00K | 150,000 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.